Alkermes (ALKS) Competitors

Biogen (NASDAQ:BIIB) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Do analysts prefer BIIB or ALKS?

Biogen currently has a consensus price target of $191.30, indicating a potential upside of 46.53%. Alkermes has a consensus price target of $38.33, indicating a potential upside of 21.04%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38
Alkermes	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

Which has more risk and volatility, BIIB or ALKS?

Biogen has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Does the media prefer BIIB or ALKS?

In the previous week, Biogen had 20 more articles in the media than Alkermes. MarketBeat recorded 30 mentions for Biogen and 10 mentions for Alkermes. Alkermes' average media sentiment score of 1.54 beat Biogen's score of 1.34 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	23 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has higher valuation and earnings, BIIB or ALKS?

Biogen has higher revenue and earnings than Alkermes. Biogen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.82B	1.95	$1.63B	$10.13	12.89
Alkermes	$1.51B	3.45	$367.07M	$2.09	15.15

Do institutionals and insiders hold more shares of BIIB or ALKS?

87.9% of Biogen shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 4.4% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in BIIB or ALKS?

Biogen received 1119 more outperform votes than Alkermes when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 70.15% of users gave Alkermes an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1824 71.28%	Underperform Votes 735 28.72%
Alkermes	Outperform Votes 705 70.15%	Underperform Votes 300 29.85%

Is BIIB or ALKS more profitable?

Alkermes has a net margin of 23.57% compared to Biogen's net margin of 16.87%. Alkermes' return on equity of 30.80% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Alkermes	23.57%	30.80%	19.09%

Summary

Alkermes beats Biogen on 11 of the 19 factors compared between the two stocks.